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It is easy to be fascinated by dendritic cells (DCs), not
only because of their pivotal role in the immune response,
but also because of the elegance with which they perform
their tasks. Although DCs comprise multiple subsets (Liu,
2001 [this issue of Cell]), all are unusually effective at antigen processing and presentation. DCs can take up a diverse array of antigens and present them to T cells as
peptides bound to both MHC class I and II products.
Relative to other antigen presenting cells, DCs are adept
at stimulating naı̈ve T cells. DCs also control the quality
of the T cell response, driving naı̈ve lymphocytes into
distinct classes of effectors. These antigen-specific, adaptive responses are critical for resistance to infections and
tumors. Conversely, DCs can also generate regulatory T
cells that suppress activated T cells, a function of likely
importance in autoimmunity and transplant rejection.
In addition to their role in adaptive responses, DCs
play a critical role in innate immunity. In some respects,
DCs are as active in responding to microbial challenge
as DCs can produce copious amounts of cytokines involved in host defense, such as IL-12 and both type I
and II interferons. DCs also activate NK and NKT cells,
innate lymphocytes that rapidly kill select targets and
produce important cytokines.
Initiating immunity may be only half of the story, however.
It is becoming increasingly clear that DCs also capture
antigens against which immunity is normally avoided. These
include environmental proteins chronically found in the respiratory and digestive tracts (Vermaelen et al., 2001), as
well as self antigens derived from tissues exhibiting constitutive cell turnover (Huang et al., 2000). Conceivably, the
capture of proteins in the steady state, i.e., in the absence
of microbial or other perturbations, allows DCs to control
tolerance to self and “normal” environmental constituents.
How is it that DCs can mediate such diverse, almost
contradictory functions in the immune response and do
so with such efficiency? Here, we concentrate on newly
appreciated specializations that enable DCs to capture
and process antigens in a distinct manner relative to
other antigen presenting cells. These qualitative and
quantitative distinctions are regulated by inflammatory
and microbial stimuli in a developmental process termed
“maturation.” In effect, maturation couples innate to
adaptive responses and is potentially pivotal in the selfnonself distinction orchestrated by DCs.
Terminal Differentiation Determines Immunity
DCs in culture exist in two functionally and phenotypically
distinct states, immature and mature (Figure 1). Immature
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cells are adept at endocytosis and express relatively low
levels of surface MHC class I and II products and costimulatory molecules (e.g., CD86). Abundant MHC class II molecules are synthesized, but they are mainly sequestered
intracellularly in late endocytic compartments (lysosomes; Figure 1, left). As in other MHC class II-expressing cells, the majority of new class II molecules are targeted
directly to endosomes and lysosomes following their diversion from the secretory pathway upon exit from the
trans-Golgi network (Pierre et al., 1997). However, a variable fraction of MHC class II is likely to reach lysosomes
following endocytosis from the plasma membrane, particularly in monocyte-derived DCs (Cella et al., 1997).
Antigens can be avidly taken up by immature DCs and
targeted to MHC class II-positive lysosomes. However,
they are not efficiently utilized for the formation of MHC
II-peptide complexes, but are retained for use as immunogenic peptides days later (Inaba et al., 2000; Turley
et al., 2000). Immature cells do form SDS-stable class
II dimers, but their presence does not correlate with the
production of immunogenic complexes (Pierre et al.,
1997). Thus, immature DCs in culture can take up antigen
but do not present it efficiently to T cells. Most DCs in
peripheral tissues in situ are of the immature phenotype,
the prototype being Langerhans cells in the epidermis.
After detecting microbial products or proinflammatory
cytokines, immature DCs transform into mature DCs,
cells with a reduced capacity for antigen uptake but
now with an exceptional capacity for T cell stimulation.
This transition is accompanied by a dramatic cytoplasmic reorganization highlighted by a redistribution of
MHC class II from intracellular compartments to the
plasma membrane. Class II molecules appear to exit from
the lysosomes, then to reside transiently in nonlysosomal
cytoplasmic structures (class II vesicles or CIIV), and finally to accumulate on the cell surface (Figure 1, right).
In tandem, surface costimulatory molecules (CD80, CD86),
MHC class I, and T cell adhesion molecules (e.g., CD48
and CD58) are all upregulated. The maturing DCs also
upregulate the capacity to generate functional peptideMHC II complexes from newly internalized antigen or from
antigen internalized prior to the maturation signal (Inaba
et al., 2000; Turley et al., 2000). The cells extend long
“dendritic” processes (actually, membrane folds) that may
increase opportunities for T cell capture and interaction.
DCs also remodel their profile of chemokine receptors that
facilitate homing to lymphoid organs.
Much of what is known concerning DC maturation has
been learned from DC cultures, either cells differentiated
with GM-CSF and IL-4 from nongrowing human blood
monocytes or from proliferating bone marrow-derived
precursors (mouse, rat, or human). The current view has
immature DCs encountering antigen in the periphery
and carrying it to lymphoid organs, maturing en route.
While valuable in general terms, this view is probably
too simple for describing the DC system in vivo. For
example, DCs migrating from the periphery may not
always be the ones that present antigen in the lymph
nodes. Rather, migrating DCs may transfer their captured antigens to other DCs for presentation. The trans-

Cell
256

Figure 1. Dendritic Cell Maturation Induces Multiple Alterations in
the Function and Intracellular Transport of MHC Class II Molecules

fer could occur either by phagocytosis of the antigenloaded DCs (Inaba et al., 1998) or by the release of
antigen-bearing vesicles (exosomes) derived from a
DC’s lysosomal compartment (Thery et al., 1999). Another oversimplification is the idea that all DCs within a
lymph node are mature. Most DCs within lymph node
in situ may be able to form MHC-peptide complexes,
but they are otherwise immature and may function to
induce peripheral tolerance (see below).
Signals Leading to Dendritic Cell Maturation
DC maturation is typically triggered by products of microbial or viral pathogens, such as LPS, CpG DNA, or
dsRNA. For many or all of these, one or more members
of the family of Toll-like receptors (TLRs) play a critical
role (Kaisho and Akira, 2001). It remains unclear if bacterial products interact directly or indirectly with TLRs,
and in some cases, endocytosis of the maturation stimulus may precede TLR activation. The involvement of
TLRs in maturation provides an attractive mechanism
by which DCs link innate to adaptive immunity.
Proinflammatory cytokines, such as TNF␣ and IL-1␤
also trigger maturation, as does ligation of CD40, a TNF
receptor family member abundant on DCs. TLRs, IL-1R,
and TNF receptors each lead to NF-B activation, a hallmark of mature DCs. DC maturation also can be initiated
by a variety of noninflammatory and pathogen-unrelated
stimuli. In DC cultures, this is exemplified by the fact that
gentle disruption of cell-cell contacts induces maturation
(Pierre et al., 1997). We suspect that different stimuli are
likely to trigger qualitatively different states of maturation,
suggesting that either via TLRs or other receptors, DCs
“decode” environmental signals, allowing for the development of mature DCs capable of polarizing T cell responses
or inducing tolerance. It is already known, for example,
that certain maturational stimuli (e.g., LPS) will favor the
development of Th1 versus Th2 cells in vitro, in part due
to the release of IL-12 by DCs that induce Th1 polarity.
Dendritic Cell Maturation and Endocytosis
Most immature DCs exhibit three types of endocytosis:
macropinocytosis, phagocytosis, and clathrin-mediated
endocytosis. In culture, the bulk of fluid uptake is
thought to reflect macropinocytic activity. Correspondingly large amounts of plasma membrane (and receptor-

bound ligands) must also be endocytosed. The internalized volumes of fluid are high, possibly explaining the
expression of aquaporins 3 and 7 which provide for
water efflux (de Baey and Lanzavecchia, 2000).
Macropinocytosis and phagocytosis are related processes, both depending on regulated actin assembly
and thus the activity of the Rho family GTPases Cdc42
and Rac (Garrett et al., 2000; West et al., 2000). Phagocytosis is triggered by the attachment of extracellular particles to surface receptors, which in turn signal particle
uptake. From an evolutionary perspective, bacterial or
particle ingestion by phagocytosis is probably the most
physiologically relevant form of antigen uptake by DCs.
In fact, derivation of antigenic peptides from phagocytosed antigens is particularly efficient (Inaba et al., 1998).
The downregulation of endocytosis begins soon after
the receipt of a maturation signal. Mechanistically, it may
reflect a reduction in levels of active (GTP-bound) Cdc42,
presumably via the regulation of a guanine nucleotide exchange factor (Garrett et al., 2000). Clathrin-coated vesicle
formation appears to continue, so mature DCs must not be
considered as being completely incapable of endocytosis.
Some DC subsets may exhibit novel strategies for
endocytosis. Epidermal Langerhans cells, for example,
reside in an environment not characterized by abundant
extracellular fluid, making it unlikely that they survey
their surroundings by macropinocytosis. An intriguing
alternative is provided by Birbeck granules (BGs), cytoplasmic membrane-bound tubules exhibiting distinct internal striations. BGs are enriched in a lectin, langerin
(CD207), whose expression even in fibroblasts can induce granule formation (Valladeau et al., 2000). It remains to be established whether langerin, or analogous
lectins, are physiologically important for antigen uptake.
Mechanisms for the Upregulation of Peptide-MHC
II Complexes During Maturation
One of the hallmarks of DC maturation is a dramatic
increase in surface MHC class II and costimulatory molecules. MHC class II products can increase some 5- to
20-fold while CD86 increases up to 100-fold. The upregulation of surface MHC class II largely reflects posttranslational events. There is only a slight increase in the
amount of MHC II mRNA following receipt of a maturation signal; in mature DCs, MHC class II synthesis actually decreases. Instead, there are major changes in the
intracellular transport of MHC class II molecules.
In immature cells, as mentioned above, new MHC
class II accumulates in late endosomes and lysosomes
while in mature DCs, class II molecules accumulate at
the cell surface (Cella et al., 1997; Pierre et al., 1997).
The reasons for this change undoubtedly reflect the
contributions of multiple factors, and may vary among
individual MHC class II haplotypes and DC populations.
One element of the mechanism, possibly unique to DCs,
may involve the regulation of cathepsin S (cat S) activity
by the specific antiprotease cystatin C (Pierre and Mellman, 1998). Cat S has a major role in the cleavage of
the MHC II-associated invariant (Ii) chain. The lumenal
aspect of Ii chain occupies the peptide binding groove
of newly synthesized MHC II ␣␤ dimers, while the cytoplasmic domain contains a lysosomal targeting signal.
In immature mouse DCs, levels of cystatin C appear
sufficient to attenuate cat S activity, slowing Ii chain
processing and favoring MHC II transport to lysosomes.
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Figure 2. Dendritic Cell Specializations that Control the Formation
of MHC-Peptide Complexes

After maturation, intracellular cystatin C decreases enhancing cat S activity and allowing a greater fraction of
new ␣␤ dimers to avoid lysosomes and reach the cell
surface. The downregulation of endocytosis must also
contribute to the enhanced residence of MHC class II on
the plasma membrane of mature DCs. Inhibiting Ii chain
cleavage in mature DCs or cystatin C-negative cells using
cat S inhibitors or cystatin C transfection restores a lysosomal pathway. This strategy is used by at least one
parasitic nematode which releases a cystatin C homolog
to negatively regulate the MHC class II pathway and
possibly evade immune detection (Manoury et al., 2001).
Even more interesting is the fate of MHC II that has
accumulated in lysosomes prior to maturation. These
molecules are somewhat more susceptible to degradation than those on the cell surface (Cella et al., 1997;
Pierre et al., 1997), but nevertheless survive 1–2 days.
Using an antibody to a hen egg lysozyme (HEL) peptideMHC II (I-Ak) complex, maturation has been found to
enhance the formation of peptide-loaded complexes
within the confines of lysosomes (Inaba et al., 2000).
These complexes then appear in CIIVs, seemingly being
sorted away from resident lysosomal components including undegraded HEL (Turley et al., 2000). The CIIVs may
deliver the complexes to the surface (Figure 1, right). This
pathway of lysosome to plasma membrane vesicle transport might be a DC-specific specialization, or at least a
pathway that is amplified or synchronously activated in
maturing DCs. Moreover, these peptide-MHC complexes
may reach the cell surface as small clusters, partly associated with CD86 (Turley et al., 2000). This specialization
may contribute to the efficiency at which DCs display
components of the immunological synapse.
The entire lysosomal system in DCs appears distinguished from that in other cells by its ability to attenuate its
proteolytic potential. Whereas cells such as macrophages
are adept at rapidly degrading internalized proteins to
amino acids, DC lysosomes can sequester antigen for
extended periods and still efficiently use the antigen for
forming peptide-MHC class II complexes (Turley et al.,
2000). We believe DC lysosomes provide a developmentally regulated environment adapted for the formation of T
cell receptor ligands. How this regulation occurs is unclear,
but may reflect overall alterations in lysosomal enzyme
content or lysosomal pH. The immunosuppressive cytokine IL-10 may act in this way to restrict the proteolytic
function of monocyte-derived DCs (Fiebiger et al., 2001).

Antigen Presentation on MHC Class I:
Breaking Convention
Compared to MHC class II, relatively little effort has yet
been focused on MHC class I-restricted antigen presentation in DCs. MHC class I does not accumulate in the
lysosomes of immature mouse DCs (although it may in
immature LCs), but it too is upregulated upon maturation, possibly reaching the surface in part together with
class II molecules (Turley et al., 2000). Maturation may
drive the formation of “immunoproteasomes,” a combinatorial form of the proteasome that influences the peptides destined to be presented on MHC class I. Most
intriguingly, DCs are specialized to form MHC class I
peptide complexes by what is called the “exogenous”
or “cross presenting” pathway.
Classically, the MHC I pathway provides for the presentation of endogenous cellular antigens. For example,
in virus-infected cells, viral proteins expressed in the
cytosol are subject to proteasomal proteolysis and the
resulting peptides translocated via TAP transporters
into the ER lumen for loading onto waiting MHC I molecules. This paradigm may provide some difficulty for
DCs, however. A priori, it seems unlikely that all viruses
can infect DCs. One alternative is that DCs encounter
infected cells in the periphery, phagocytosing the dying
cells via receptors specific for such forms of uptake
(e.g., ␣V ␤5 integrins). Indeed, immature DCs take up
dying cells avidly and then “cross-present” viral antigens from the infected cells to CD8⫹ T cells (Albert et
al., 1998). Several reports have shown that DCs also
process tumor antigens from phagocytosed tumor cells
for presentation on MHC I (and MHC II).
Soluble exogenous antigens also can be cross-presented from nonreplicating microbes and immune complexes, the latter taken up via Fc receptors (Rodriguez
et al., 1999). Uptake of the same antigens by Fc␥R on
macrophages and B cells does not result in efficient
MHC I-restricted presentation. DCs seem to allow the
egress of the internalized antigen (3–12 kDa fragments)
from endocytic organelles into the cytosol (Rodriguez
et al., 1999). From here, the fragments enter the “conventional” MHC I pathway involving proteasomal proteolysis and TAP translocation. Exogenous pathways to MHC
class I are especially evident in DCs, but other cells, like
liver sinusoidal endothelial lining cells and macrophages, may have this potential. Although little is known
about the mechanism of cross-presentation, we suspect
far more will rapidly emerge concerning the cell biology
of this pathway and its regulation during DC maturation.
Antigen Presentation and Tolerance
Transferring what is being learned in vitro to DCs in situ
represents an important challenge. One approach to the
problem will involve the use of antigens modified to allow
selective targeting DC-specific surface receptors. One
such receptor is the multilectin DEC-205 (Mahnke et al.,
2000). In or preliminary results, test antigens such as HEL
were fused to anti-DEC-205 antibodies, injected into mice,
and shown to generate DCs with MHC class II-peptide
complexes capable of eliciting T cell responses in vitro and
in vivo. Interestingly, the in vivo response was transient,
rendering the mice refractory to subsequent injections of
HEL, even in Freund’s adjuvant. In other words, the animals
were apparently tolerized to HEL. Tolerance was converted to immunity, however, if the anti-DEC/HEL fusion
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protein was injected together with a maturation signal, e.g.,
anti-CD40. Thus, as predicted from the in vitro studies,
immunization requires DC maturation, but tolerance may
be induced by DCs that have not been induced to mature.
How can this happen if immature cells are incapable of
forming MHC-peptide complexes?
So-called immature DCs in lymphoid tissues seem to
have one major difference from their in vitro-generated
counterparts: the presence of large amounts of MHC
products and MHC-peptide complexes on the surface
of DCs in vivo (Inaba et al., 1998). While this is a feature
of mature DCs, these cells in vivo otherwise exhibit features of immature DCs. Thus, “immature” DCs in
lymphoid organs are endocytically active and express
relatively low levels of key costimulatory molecules like
CD86 and CD40. The capacity to form MHC-peptide
complexes in the absence of a maturation stimulus and
in the absence of other changes (costimulatory molecules, chemokine receptors) that allow mature DCs to
stimulate immunity, may be critical for DCs in situ to be
able to tolerize T cells in the steady state.
In constructing a cell type with a broad and efficient
capacity for antigen presentation (Figure 2), the immune
system seems to have engaged in a Faustian bargain.
The factors that contribute to the DC’s capacity for immunity create an equivalent potential for the generation
of T cell responses to self antigens and environmental
proteins. In fact, DCs in intestinal lymphatics constitutively seem to have captured proteins placed in the
gut lumen and fragments of epithelial cells themselves
(Huang et al., 2000). Likewise, DCs that line our airways
transport soluble macromolecules from the airway to
the lymph nodes in the chest (Vermaelen et al., 2001).
In these cases, if DCs were to be immunogenic, chronic
inflammation would ensue. However, there is growing
evidence that DCs in lymphoid organs maintain peripheral tolerance (Heath and Carbone, 2001).
We regard the role of DCs in peripheral tolerance to
be intimately related to their function in immunity, the
latter depending on DC maturation signals. Many selfreactive T cells must escape the negative selection
events in the thymus. Other self antigens may never
reach the thymus, particularly during neonatal life when
the T cell repertoire begins to be shaped. Similarly, many
environmental proteins, e.g., microbial and plant proteins, bathe our respiratory tract and intestines beginning postnatally, long after the thymus has had a chance
to delete T cells that are potentially reactive to “self.”
When an inflammatory or infectious situation arises, the
maturing DCs are likely to present at least some of these
self and environmental proteins together with the microbial peptides. Some of the specializations in Figure 2
would allow DCs to present these proteins on MHC
class I and II in the steady state, prior to encounter with
pathogens. As such, the capacity of immature DCs to
delete antigen-specific T cells peripherally, or to generate regulatory T cells, may safeguard against autoimmunity and chronic inflammation when infection strikes.
At first, the processing of proteins from other cells seems
to violate the beauty of MHC restriction. This elegant part of
cell-mediated immunity focuses T cells on infected targets.
Cross presentation, in effect, moves peptides from infected
cells to noninfected DCs. Because it occurs primarily in
DCs, however, cross presentation is, we suspect, critical

in tolerizing the T cell repertoire peripherally, and also allows
simultaneous sampling of both the MHC class I and class
II systems. MHC restriction therefore remains intact for
other cells and stages of the T cell response.
The analysis of DC function in T cell-mediated immunity has always involved three parallel paths of research:
the uptake and presentation of antigens, the cytokines
and surface molecules that control the quality and quantity of the T cell response, and the properties required to
distribute and mobilize DCs in vivo. We have considered
mechanisms underlying the first topic, stressing the specializations of these antigen processing machines and the
importance of DC maturation (Figure 2). A major unknown
remains the endocytic and processing capacities of DCs
in situ. The cell biology of DCs in vivo will benefit considerably from approaches that involve selective targeting of
antigens to DCs in situ, as in the DEC-205 work cited
above, imaging studies, selective genetic manipulation
of DCs in situ, and continued attention to fundamental
mechanisms defined in culture. Understanding the cell
biological basis for DC function has emerged as an important and rich area. We suspect it will hold the key to
understanding how DCs maintain the balance between
tolerance for self and immunity against pathogens.
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